Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals to purchase orphan drugs at discounted rates through the 340B program as long as the orphan drug is used to treat illnesses or conditions other than the rare illnesses or conditions for which the orphan drug designation was originally given.

Related News Articles

Headline
The House Budget Committee today held a hearing on the Congressional Budget Office’s recent report on key design components and considerations for policymakers…
Headline
The Centers for Medicare…
Headline
The AHA and other plaintiffs late Friday asked a federal district judge to set a firm June deadline for the Department of Health and Human Services to propose…
Headline
The AHA today responded to a RAND Corporation study that found that certain prices paid to hospitals by private health plans are high relative to Medicare and…
Headline
A federal district court judge yesterday ruled that the Department of Health and Human Services would get "first crack at crafting appropriate remedial…
Headline
The Centers for Medicare…